Bill > HR1717

This bill, the Interagency Patent Coordination and Improvement Act of 2023, aims to establish an Interagency Task Force on Patents between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). The key provisions include: requiring the USPTO Director to consult with the FDA Commissioner on patent decisions or actions involving human drugs and biological products; establishing the Task Force to coordinate communication, evaluation, and implementation of activities between the two agencies regarding patents; requiring the sharing of information such as new patent approvals, drug and biological product approvals, and relevant scientific data; and establishing protocols to safeguard confidentiality of shared information. The bill also requires a report from the USPTO Director on the Task Force's effectiveness and recommendations for potential improvements.